Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of intravesical legusitaxel injection for bladder cancer
CTR20261076Phase 2Active
- Sponsor
- Shanghai Qinheli Biotechnology
- Start
- Mar 2026
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of legusitaxel in non-muscle-invasive bladder cancer (NMIBC), sponsored by Shanghai Qinheli Biotechnology. Started Mar 2026; status: active.
02
Drugs
legusitaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20261076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261076.